The platinum-containing chemotherapeutic agents remain key components of many of the most effective regimens for the treatment of cancer. New information about the chemistry, pharmacology and molecular mechanisms by which these drugs work is leading to both the development of new drugs and more effective use of existing members of this class. Better definition of the genetic basis of malignancies is offering intriguing new insights in to how to use these drugs in a more individualized manner. "Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications", edited by Andrea Bonetti, Steve B. Howell, Roberto Leone, and Franco Muggia, provides succinct summaries of the major new developments in field of platinum drug therapy drawn from presentations made at the 10th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy that took place in Verona, Italy, in December 2007. This meeting, held once every 4 years, brought together the world’s leading investigators working on platinum drugs and their contributions provide a detailed survey of the major research directions in this rapidly evolving field.
Author(s): Franco M. Muggia (auth.), Andrea Bonetti, Roberto Leone, Franco M. Muggia, Stephen B. Howell (eds.)
Series: Cancer Drug Discovery and Development
Edition: 1
Publisher: Humana Press
Year: 2009
Language: English
Pages: 383
Tags: Cancer Research; Pharmacology/Toxicology
Front Matter....Pages i-xxvi
Platinum Compounds: The Culmination of the Era of Cancer Chemotherapy....Pages 1-7
Studies on New Platinum Compounds....Pages 11-17
Assessment of the In Vivo Antiproliferative Activity of a Novel Platinum Particulate Pharmacophore....Pages 19-25
Nanocapsules of Platinum-Based Anticancer Drugs....Pages 27-32
The Design and Development of the Tumor-Targeting Nanopolymer Dach Platinum Conjugate AP5346 (Prolindac ™ )....Pages 33-39
In vitro Anti-proliferative Effects of ProLindac™, a Novel Dach-Platinum-Linked Polymer Compound, as a Single Agent and in Combination with Other Anti-cancer Drugs....Pages 41-47
Synthesis of Cisplatin Analogues: Cytotoxic Efficacy and Anti-tumour Activity of Bis-Amidine and Bis-Iminoether Pt(II) Complexes....Pages 49-56
Ruthenium Drugs for Cancer Chemotherapy: An Ongoing Challenge to Treat Solid Tumours....Pages 57-66
X-ray Crystal Structure of a Monofunctional Platinum–DNA Adduct, cis -{Pt(NH 3 ) 2 -(Pyridine)} 2+ Bound to Deoxyguanosine in a Dodecamer Duplex....Pages 67-72
Osmium Arenes: A New Class of Potential Anti-cancer Agents....Pages 73-79
Resistance to Cisplatin Results from Multiple Mechanisms in Cancer Cells....Pages 83-88
CTR1 as a Determinant of Platinum Drug Transport....Pages 89-94
Regulation of the Export of Platinum-Containing Drugs by the Copper Efflux Transporters ATP7A and ATP7B....Pages 95-99
Altered Localization of Transport Proteins Associated with Cisplatin Resistance....Pages 101-107
How to Overcome Cisplatin Resistance Through Proton Pump Inhibitors....Pages 109-114
Cellular Resistance to Oxaliplatin and Drug Accumulation Defects....Pages 115-124
Possible Incorporation of Free N7 -Platinated Guanines in DNA by DNA Polymerases, Relevance for the Cisplatin Mechanism of Action....Pages 125-132
Structural and Mechanistic Studies of Anticancer Platinum Drugs: Uptake, Activation, and the Cellular Response to DNA Binding....Pages 135-147
Platinum Drugs and DNA Repair: Lessons from the NCI Panel and Clinical Correlates....Pages 149-155
Differences in Conformation and Conformational Dynamics Between Cisplatin and Oxaliplatin DNA Adducts....Pages 157-169
Regrowth Resistance: Low-Level Platinum Resistance Mediated by Rapid Recovery from Platinum-Induced Cell-Cycle Arrest....Pages 171-176
Targeting Nucleotide Excision Repair as a Mechanism to Increase Cisplatin Efficacy....Pages 177-187
CHK2 and ERCC1 in the DNA Adduct Repair Pathway that Mediates Acquired Cisplatin Resistance....Pages 189-194
Modulation of Survival Pathways in Ovarian Carcinoma Cells Resistant to Platinum Compounds....Pages 195-200
Paraptotic Cell Death Induced by the Thioxotriazole Copper Complex A0: A New Tool to Kill Apoptosis-Resistant Cancer Cells....Pages 201-207
Platinum Compounds and Radiation....Pages 211-223
Treating Cisplatin-Resistant Cancer: A Systematic Analysis of Oxaliplatin or Paclitaxel Salvage Chemotherapy....Pages 225-230
Platinum Compounds in Lung Cancer: Current Status....Pages 231-242
Is Lipoplatinum Monotherapy an Active Alternative in Second Line Treatment of Metastatic Non–Small Cell Lung Cancer? A Phase II Trial....Pages 243-249
Combining Platinums in Gastric Cancer....Pages 251-270
Oxaliplatin-Based Chemotherapy for Colon Cancer....Pages 271-284
First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients....Pages 285-293
Pre-operative Radio-Chemotherapy of Rectal Cancer: Toxicity and Preliminary Results with the Addition of Weekly Oxaliplatin....Pages 295-306
The Role of Platins in Newly Diagnosed Endometrial Cancer....Pages 307-315
Platinum Compounds: Key Ingredients in Ovarian Cancer Treatment and Strategies....Pages 317-328
Intraperitoneal Chemotherapy: An Important Strategy in Ovarian Cancer Treatment....Pages 329-333
Novel Strategies for Enhancing the Efficacy of Intraperitoneal Chemotherapy for Patients with Ovarian Cancer....Pages 335-341
Laparoscopically Assisted Heated Intra-Operative Intraperitoneal Chemotherapy (HIPEC): Technical Aspect and Pharmacokinetics Data....Pages 343-351
Organic Cation Transporters 2 as Mediators of Cisplatin Nephrotoxicity....Pages 353-358
Peripheral Neurotoxicity of Platinum Compounds....Pages 359-364
Platinum Drugs in Children with Cancer....Pages 365-371
Optimising Carboplatin Dose using Patient Characteristics and Therapeutic Drug Monitoring....Pages 373-380
Back Matter....Pages 379-383
